

**Stuart B. Levy, M.D.**

Stuart B. Levy, M.D., Professor of Molecular Biology and Microbiology and of Medicine, is the Director of the Center for Adaptation Genetics and Drug Resistance at Tufts University School of Medicine and Staff Physician at the Tufts Medical Center. He also serves as President of the international *Alliance for the Prudent Use of Antibiotics*, and is co-founder and Chief Scientific Officer of Paratek Pharmaceuticals, Inc. He is a past President of the *American Society for Microbiology*.

Dr. Levy led the discovery of the first energy-dependent antibiotic efflux mechanism and efflux protein (for tetracyclines). His research into multi-drug resistance revealed a regulatory locus, *mar*, for intrinsic antibiotic resistance and virulence among the *Enterobacteriaceae* and other bacteria. He led the first, and perhaps only, prospective farm study showing that feed containing low-dose antibiotics led to the emergence of antibiotic resistance in animals and the farm family. He has published over 300 papers, edited four books and two special journal editions devoted to antibiotic use and resistance. His 1992 book, *The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle*, now in its second edition, has been translated into four languages.

Dr. Levy received his medical degree from the University of Pennsylvania, completed his residency at Mt. Sinai Hospital in New York and performed postdoctoral research at the National Institutes of Health. He is a Fellow of the American College of Physicians, Infectious Disease Society of America, the American Academy of Microbiology and the Association for the Advancement of Science. He was Chairperson of the U.S. Fogarty Center study of "Antibiotic use and resistance worldwide" and helped write the U.S. Office of Technology Assessment report on antibiotic resistant bacteria. He consults for international and national organizations including the World Health Organization, the U.S. National Academy of Sciences and Institute of Medicine, the U.S. FDA and U.S. EPA. In 1995 he received the Hoechst-Roussel Award for esteemed research in antimicrobial chemotherapy from the American Society for Microbiology and has been awarded honorary degrees from Wesleyan and Des Moines Universities.